J.P. Morgan 2024: Financial Forecast Is Sunny For Firms Poised For Pharma Deals
Clouds Seemed To Lift At Annual Industry Meeting
Executive Summary
Drug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.